O'Day Daniel Patrick reported option exercise involving 102,619 shares of GILEAD SCIENCES, INC. at $72.34 for $7.42M on Nov 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chairman & CEO
Chairman & CEO
Filed Nov 6, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$7,423,458.46Shares × reported price
Shares traded
102,619Common Stock
Price per share
$72.34Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
654,302Direct
Trade date
Nov 4, 2026Option exercise
Filed
Nov 6, 2026, 5:15 PM ET2-day reporting delay
Accession
0001638643-26-000040Code M · Transaction 395191
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 4, 2026Option exercise102,619$0.00$0Trade 395195
Nov 5, 2026Option exercise9,810$0.00$0Trade 395196
Nov 5, 2026Option exercise9,810$72.34$709,655.40Trade 395193
Nov 4, 2026Sell102,619$175.16−$17,975,021.11Trade 395192
Nov 5, 2026Sell9,810$175.17−$1,718,417.70Trade 395194
6 transaction rows in this filing. Joint filers share the same rows.

GILD price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GILD · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago −4.6%1d ago +0.3%
Returns since7d +0.7%30d90d180d1y

Footnotes in full

F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. F2: Sale prices for the transactions reported range from $175.05 to $175.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. F3: The stock options have a four-year vesting schedule. 25% of the stock options vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.